Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women

Breast Cancer Research and Treatment

Volumn 108, Issue 1, 2008, Pages 57-67

  Johansson, Harriet ^a   Gandini, Sara ^a   Bonanni, Bernardo ^a   Mariette, Frederique ^a   Guerrieri Gonzaga, Aliana ^a   Serrano, Davide ^a   Cassano, Enrico ^a   Ramazzotto, Francesca ^c   Baglietto, Laura ^b   Sandri, Maria Teresa ^a   Decensi, Andrea ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

^c Obstetrics and Gynecology   (Italy)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

Biomarkers; Breast cancer risk; C terminal cross link telopeptide; Insulin like growth factor I; Mammographic density; Prolactin; Sex steroid hormones

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; FOLLITROPIN; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ANALYTIC METHOD; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

BODY MASS INDEX; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; PROLACTIN; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN;

EID: 40249120009     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9577-9     Document Type: Article

References (54)

1. Shull JD, Spady TJ, Snyder MC et al (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18:1595-1601
2. Yue W, Santen RJ, Wang JP et al (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86:477-486
3. Feinleib M (1968) Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41:315-329
4. Ingle JN (2005) Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 11:900s-905s
5. Key T, Appleby P, Barnes I et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616
6. Kaaks R, Berrino F, Key T et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97:755-765
7. Cummings SR, Lee JS, Lui LY et al (2005) Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 14:1047-1051
8. Ellis MJ, Jenkins S, Hanfelt J et al (1998) Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 52:175-184
9. Schernhammer ES, Holly JM, Pollak MN et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699-704
10. Toniolo P, Bruning PF, Akhmedkhanov A et al (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828-832
11. Yu H, Jin F, Shu XO et al (2002) Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11:705-712
12. Yu H, Shu XO, Li BDL et al (2003) Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev 12:1067-1073
13. Boyd NF, Lockwood GA, Byng JW et al (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:1133-1144
14. Boyd NF, Stone J, Martin LJ et al (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87:876-882
15. Byrne C, Colditz GA, Willett WC et al (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744-3748
16. Maskarinec G, Williams AE, Kaaks R (2003) A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991-996
17. Lai JH, Vesprini D, Zhang W et al (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573-582
18. Deal C, Ma J, Wilkin F et al (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274-1280
19. Aiello EJ, Tworoger SS, Yasui Y et al (2005) Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:1411-1417
20. Greendale GA, Palla SL, Ursin G et al (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162:826-834
21. Noh JJ, Maskarinec G, Pagano I et al (2006) Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 15:20-28
22. Tamimi RM, Hankinson SE, Colditz GA et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:2641-2647
23. Warren R, Skinner J, Sala E et al (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:1502-1508
24. Decensi A, Bonanni B, Baglietto L et al (2004) A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res 10:4389-4397
25. Boyd N, Martin L, Stone J et al (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11:1048-1053
26. SAS Institute Inc (1990) SAS/STATTM User's Guide. SAS Institute Inc, USA, Cary, NC
27. Boyd NF, Lockwood GA, Martin LJ et al (1998) Mammographic densities and breast cancer risk. Breast Dis 10:113-126
28. Greendale GA, Reboussin BA, Slone S et al (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30-37
29. Spicer DV, Ursin G, Parisky YR et al (1994) Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86:431-436
30. Brisson J, Brisson B, Cote G et al (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9:911-915
31. Cuzick J, Warwick J, Pinney E et al (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621-628
32. Diorio C, Pollak M, Byrne C et al (2005) Insulin-Like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14:1065-1073
33. Ben Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763
34. Lonning PE, Helle SI, Johannessen DC et al (1995) Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol 42:23-30
35. Key TJ, Appleby PN, Reeves GK et al (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218-1226
36. Kalish GM, Barrett-Connor E, Laughlin GA et al (2003) Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 88:1646-1652
37. Sowers M, Derby C, Jannausch ML et al (2003) Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 88:4904-4910
38. Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150:161-171
39. Chailurkit LO, Ongphiphadhanakul B, Piaseu N et al (2001) Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 47:1083-1088
40. Boyd NF, Lockwood GA, Byng JW et al (1998) The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer 78:1233-1238
41. Brandt Van den PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514-527
42. Potischman N, Swanson CA, Siiteri P et al (1996) Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88:756-758
43. Labrie F, Luu-The V, Labrie C et al (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152-182
44. Mouridsen HT, Rose C, Brodie AH et al (2003) Challenges in the endocrine management of breast cancer. Breast 12(2):S2-S19
45. Szymczak J, Milewicz A, Thijssen JH et al (1998) Concentration of sex steroids in adipose tissue after menopause. Steroids 63:319-321
46. Clevenger CV, Furth PA, Hankinson SE et al (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1-27
47. Tworoger SS, Eliassen AH, Rosner B et al (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814-6819
48. Eliassen AH, Tworoger SS, Hankinson SE (2007) Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 120:1536-1541
49. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727
50. Jernstrom H, Deal C, Wilkin F et al (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377-384
51. Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548
52. Sala E, Warren R, McCann J et al (2000) Smoking and high-risk mammographic parenchymal patterns: a case-control study. Breast Cancer Res 2:59-63
53. Warwick J, Pinney E, Warren RM et al (2003) Breast density and breast cancer risk factors in a high-risk population. Breast 12:10-16
54. Tanko LB, Christiansen C (2004) An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause 11:104-109